JPRN-jRCT2080223605已完成1 期
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-906 in Japanese Healthy Male Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 60age old（—）
- 性别
- Male
入选标准
- •1.In the opinion of the investigator or sub-investigator, the participant is capable of understanding and complying with protocol requirements.
- •2.The participant signs and dates a written, informed consent form prior to the initiation of any study procedures.
- •3.The participant is a Japanese healthy adult male, aged 20 to 60 years, inclusive, at the time of informed consent.
- •4.The participant weighs at least 50 kg and has a body mass index (BMI) from 18.5 to 25 kg/m2, inclusive at Screening.
- •5.A male participant who is nonsterilized and sexually active with a female partner of childbearing potential agrees to use adequate contraception from the signing of informed consent to 12 weeks (84 days) after the last dose of study drug. The female partner of a male participant should also be advised to use adequate contraception.
排除标准
- •1.The participant has received any investigational compound within 16 weeks (112 days) prior to the first dose of study drug.
- •2.The participant has received TAK-906 in a previous clinical study or as a therapeutic agent.
- •3.The participant is an immediate family member of or an investigational site employee, or is in a dependent relationship with an investigational site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
- •4.The participant has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality, which may impact the ability of the participant to participate in the study or potentially confound its results.
- •5.The participant has a history of any psychiatric disease that would interfere with the evaluation of study drug activity (prolactin concentration) or safety.
- •6.The participant has a history of seizure or tardive dyskinesia.
- •7.The participant has a history of hyperprolactinemia, pituitary adenoma, and/or hypothyroidism.
- •8.The participant has a family history of prolonged QT.
- •9.The participant has undergone previous gastric bypass surgery or currently nad a gastric band fitted.
- •10.The participant has dysphagia and/or inability to swallow study medication whole.
- •11.The participant has a known hypersensitivity to any component of the TAK-906 formulation or related compounds.
- •12.The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 2 years prior to the Screening visit, or is unwilling to agree to abstain from alcohol and drugs throughout the study, or has a positive urine test result for drugs of abuse or a positive alcohol screen (urine alcohol test/breath test) result for alcohol at Screening.
- •13.The participant has taken any excluded medication, supplements, or dietary products during the time periods listed in the Excluded Medications, Supplements, and Dietary Products table.
- •14.If male, the participant intends to donate sperm during the course of this study or for at least 12 weeks (84 days) after the last dose of study drug.
- •15.The participant has current or recent (within 24 weeks [168 days]) gastrointestinal disease that would be expected to influence the absorption of drugs (ie, a history of malabsorption, esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent [more than once per week] occurrence of heartburn, or any surgical intervention).
- •16.The participant has a history of cancer, except basal cell carcinoma which has been in remission for at least 5 years prior to Day 1.
- •17.The participant has a positive test result for hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiencyvirus (HIV) antibody/antigen, or serological reactions for syphilis at Screening.
- •18.The participant has used nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patch or nicotine gum) within 4 weeks (28 days) prior to the first dose of study drug. Cotinine test is positive at Screening.
- •19.The participant has poor peripheral venous access.
- •20.The participant has undergone whole blood collection of at least 200 mL within 4 weeks (28 days) or at least 400 mL within 12 weeks (84 days) prior to the start of study drug administration.
- •21.The participant has undergone whole blood collection of at least 800 m
研究者
相似试验
已完成
1 期
Safety, Tolerability and Pharmacokinetics of ALD1910MigraineACTRN12619001380189Alder BioPharmaceuticals, Inc.96
招募中
2 期
A 6 Month Study to Evaluate the Efficacy, Safety and Tolerability of drug â??Sarizotanâ?? in Patients with Rett Syndrome having difficulty in breathing. This is a Randomized, Double-Blind (the doctor and the patient not knowing the treatment), Placebo (inactive substance) -Controlled study.CTRI/2017/01/007738ewron Pharmaceuticals SpA
已完成
1 期
A Single and Multiple Daily Injection Study of DUR-928 in Healthy Volunteers.ACTRN12615000903583INC Research44
进行中（未招募）
1 期
Sarizotan: Treatment in patients with Rett Syndrome with Respiratory Symptoms.Rett syndromeMedDRA version: 20.0Level: LLTClassification code 10039000Term: Rett's disorderSystem Organ Class: 100000004850EUCTR2015-004448-20-GBewron Pharmaceuticals S.p.A.129
尚未招募
不适用
A single Dose Clinical study to evaluate the efficacy of a Health supplement on energy ezxpenditureCTRI/2020/04/024679OmniActive Health Technologies Ltd